Europe
Funds will support UK commercial launch and FDA 510(k) submission later this year
Researchers with the LEO Foundation Skin Immunology Research Center at the Faculty of Health and Medical Sciences, the University of Copenhagen, showed that aggressive antibiotic treatment could not only inhibit the staph infection, but also the cancer cells.
Sanofi reported overall net sales increased by 5.5% for the second quarter, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
The new company will be helmed by Mylan’s Michael Goettler and is expected to generate 2020 revenues of $19 to $20 billion.
We embarked upon the landmark Phase III PARAGON-HF trial to determine whether sacubitril/valsartan could have a meaningful impact on the treatment of HFpEF, as it does in the treatment of heart failure with reduced ejection fraction,” stated John McMurray, professor of Medical Cardiology at University of Glasgow and PARAGON-HF Executive Committee Co-Chair.
A study conducted in 2016 by nova-Institute on behalf of the Bio-based Industries Consortium showed for the first time which macroeconomic effects are generated by the bioeconomy e.g. turnover and employment for the years 2008 and 2013.
A number of companies reported clinical trial data last week. Here’s a look.
Janssen will present data from the trial at a September conference in Stockholm. The company plans to seek FDA approval later this year.
A new study identifies the risk factors that could help healthcare providers recognize patients being treated for diabetes who are most likely to have low blood sugar.
Galapagos NV announces its unaudited first half-year results, which are further detailed in its H1 2019 report available on the Galapagos website, www.glpg.com.
PRESS RELEASES